Agathe Béranger1,2, Sihem Benaboud3,4, Saïk Urien5,3, Florence Moulin6, Emmanuelle Bille7, Fabrice Lesage6, Yi Zheng4, Mathieu Genuini6, Inès Gana4, Sylvain Renolleau6, Déborah Hirt3,4, Jean-Marc Tréluyer5,3,4, Mehdi Oualha3,6. 1. Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, Université Paris Descartes, Sorbonne-Paris Cité, 149 rue de Sèvres, 75015, Paris, France. agathe.beranger@aphp.fr. 2. EA7323, Evaluation des thérapeutiques et pharmacologie périnatale et pédiatrique, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. agathe.beranger@aphp.fr. 3. EA7323, Evaluation des thérapeutiques et pharmacologie périnatale et pédiatrique, Université Paris Descartes, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. 4. Service de pharmacologie clinique, Hôpital Cochin, Université Paris Descartes, Sorbonne-Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. 5. Unité de Recherche Clinique-Centre d'Investigation Clinique, Hôpital Cochin-Necker, Université Paris Descartes, Sorbonne-Paris Cité, 149 rue de Sèvres, 75015, Paris, France. 6. Service de réanimation et surveillance continue médico-chirurgicales, Hôpital Necker Enfants-Malades, Université Paris Descartes, Sorbonne-Paris Cité, 149 rue de Sèvres, 75015, Paris, France. 7. Laboratoire de microbiologie, Hôpital Necker Enfants-Malades, Université Paris Descartes, Sorbonne-Paris Cité, 149 rue de Sèvres, 75015, Paris, France.
Abstract
BACKGROUND: Critically ill children frequently display observed alterations of pharmacokinetic (PK) parameters, leading to a reduction in β-lactam concentrations. This study aimed to develop a PK population model for piperacillin in order to optimize individual dosing regimens. METHODS: All children aged ≤ 18 years, weighing more than 2.5 kg, and receiving piperacillin infusions were included in this study. Piperacillin was quantified by high-performance liquid chromatography, and PK were described using the non-linear mixed-effect modeling software MONOLIX. Monte Carlo simulations were used to optimize dosing regimens in order to attain two PK targets: 50% fT>MIC and 100% fT>MIC. RESULTS: We included 50 children with a median (range) postnatal age of 2.3 years (0.1-18), body weight (BW) of 11.9 kg (2.7-50), Pediatric Logistic Organ Dysfunction-2 (PELOD-2) severity score of 4 (0-16), and estimated glomerular filtration rate (eGFR) of 142 mL.min-1.1.73 m-2 (29-675). A one-compartment model with first-order elimination adequately described the data. Median (range) values for piperacillin clearance (CL) and volume of distribution were 3 L.h-1 (0.71-10) and 0.33 L.kg-1 (0.21-0.86), respectively. BW was integrated with the allometric relationship. eGFR and PELOD-2 severity score were the covariates explaining between-subject variability in CL and volume, respectively. According to the simulations, extended and continuous infusion provided the highest probability of reaching the target of 50% fT>MIC and 100% fT>MIC for normal and augmented renal clearance, respectively. CONCLUSIONS: Unlike standard intermittent piperacillin dosing regimens, extended and continuous infusion allows the PK targets to be reached, for children with normal or augmented renal clearance. TRIAL REGISTRATION NUMBER: Registered at http://www.clinicaltrials.gov (NCT02539407).
BACKGROUND: Critically ill children frequently display observed alterations of pharmacokinetic (PK) parameters, leading to a reduction in β-lactam concentrations. This study aimed to develop a PK population model for piperacillin in order to optimize individual dosing regimens. METHODS: All children aged ≤ 18 years, weighing more than 2.5 kg, and receiving piperacillin infusions were included in this study. Piperacillin was quantified by high-performance liquid chromatography, and PK were described using the non-linear mixed-effect modeling software MONOLIX. Monte Carlo simulations were used to optimize dosing regimens in order to attain two PK targets: 50% fT>MIC and 100% fT>MIC. RESULTS: We included 50 children with a median (range) postnatal age of 2.3 years (0.1-18), body weight (BW) of 11.9 kg (2.7-50), Pediatric Logistic Organ Dysfunction-2 (PELOD-2) severity score of 4 (0-16), and estimated glomerular filtration rate (eGFR) of 142 mL.min-1.1.73 m-2 (29-675). A one-compartment model with first-order elimination adequately described the data. Median (range) values for piperacillin clearance (CL) and volume of distribution were 3 L.h-1 (0.71-10) and 0.33 L.kg-1 (0.21-0.86), respectively. BW was integrated with the allometric relationship. eGFR and PELOD-2 severity score were the covariates explaining between-subject variability in CL and volume, respectively. According to the simulations, extended and continuous infusion provided the highest probability of reaching the target of 50% fT>MIC and 100% fT>MIC for normal and augmented renal clearance, respectively. CONCLUSIONS: Unlike standard intermittent piperacillin dosing regimens, extended and continuous infusion allows the PK targets to be reached, for children with normal or augmented renal clearance. TRIAL REGISTRATION NUMBER: Registered at http://www.clinicaltrials.gov (NCT02539407).
Authors: William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191
Authors: Jean-Marie Conil; Bernard Georges; Olivier Mimoz; Eric Dieye; Stéphanie Ruiz; Pierre Cougot; Kamran Samii; Georges Houin; Sylvie Saivin Journal: Intensive Care Med Date: 2006-10-24 Impact factor: 17.440
Authors: Jason A Roberts; Rob Boots; Claire M Rickard; Peter Thomas; Jo Quinn; Darren M Roberts; Brent Richards; Jeffrey Lipman Journal: J Antimicrob Chemother Date: 2006-11-28 Impact factor: 5.790
Authors: Ann Versporten; Julia Bielicki; Nico Drapier; Mike Sharland; Herman Goossens Journal: J Antimicrob Chemother Date: 2016-01-08 Impact factor: 5.790
Authors: Malin M Rhodin; Brian J Anderson; A Michael Peters; Malcolm G Coulthard; Barry Wilkins; Michael Cole; Etienne Chatelut; Anders Grubb; Gareth J Veal; Michael J Keir; Nick H G Holford Journal: Pediatr Nephrol Date: 2008-10-10 Impact factor: 3.714
Authors: Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton Journal: Clin Pharmacokinet Date: 2021-11-30 Impact factor: 6.447
Authors: Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock Journal: Pediatr Nephrol Date: 2018-10-29 Impact factor: 3.714
Authors: Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt Journal: Clin Pharmacokinet Date: 2020-02 Impact factor: 6.447
Authors: Anders Thorsted; Anders N Kristoffersson; Sabine F Maarbjerg; Henrik Schrøder; Mikala Wang; Birgitte Brock; Elisabet I Nielsen; Lena E Friberg Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: D Hirt; M Oualha; B Pasquiers; S Blanot; R Rubinstazjn; C Glorion; S El Messaoudi; D Drummond; V Lopez; J Toubiana; A Béranger; Sana Boujaafar; Yi Zheng; Carmen Capito; S Winter; P L Léger; R Berthaud; Inès Gana; F Foissac; J M Tréluyer; N Bouazza; S Benaboud Journal: Eur J Clin Pharmacol Date: 2021-06-23 Impact factor: 2.953